RNF39

Summary

RNF39 (ring finger protein 39, HGNC:18064) is a protein-coding gene on chromosome 6p22.1, encoding RING finger protein 39 (Q9H2S5). Plays an inhibitory role in anti-RNA viral innate immunity by targeting the adapter DDX3X and promoting its ‘Lys-48’-linked polyubiquitination.

This gene lies within the major histocompatibility complex class I region on chromosome 6. Studies of a similar rat protein suggest that this gene encodes a protein that plays a role in an early phase of synaptic plasticity. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 80352 — RefSeq curated summary.

At a glance

• GWAS associations: 30
• Clinical variants (ClinVar): 72 total
• MANE Select transcript: NM_025236

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18064
Approved symbol	RNF39
Name	ring finger protein 39
Location	6p22.1
Locus type	gene with protein product
Status	Approved
Aliases	HZFw1, LIRF, FAP216
Ensembl gene	ENSG00000204618
Ensembl biotype	protein_coding
OMIM	607524
Entrez	80352

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000244360, ENST00000376751

RefSeq mRNA: 2 — MANE Select: NM_025236 NM_025236, NM_170769

CCDS: CCDS4673, CCDS4674

Canonical transcript exons

ENST00000244360 — 4 exons

Exon	Start	End
ENSE00001704048	30073157	30073248
ENSE00001741114	30073456	30073478
ENSE00001825510	30075223	30075769
ENSE00001893610	30070270	30071691

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 92.67.

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	92.67	gold quality
zone of skin	UBERON:0000014	92.27	gold quality
skin of leg	UBERON:0001511	92.23	gold quality
lower esophagus mucosa	UBERON:0035834	88.21	gold quality
esophagus mucosa	UBERON:0002469	82.43	gold quality
minor salivary gland	UBERON:0001830	82.37	gold quality
saliva-secreting gland	UBERON:0001044	82.19	gold quality
vagina	UBERON:0000996	79.91	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	76.99	gold quality
prostate gland	UBERON:0002367	72.95	gold quality
right uterine tube	UBERON:0001302	72.28	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	71.73	gold quality
body of stomach	UBERON:0001161	70.26	gold quality
ectocervix	UBERON:0012249	70.06	gold quality
esophagus	UBERON:0001043	69.90	gold quality
stromal cell of endometrium	CL:0002255	69.58	gold quality
cortical plate	UBERON:0005343	68.98	gold quality
mammary gland	UBERON:0001911	68.96	gold quality
thoracic mammary gland	UBERON:0005200	68.96	gold quality
uterine cervix	UBERON:0000002	68.69	gold quality
tonsil	UBERON:0002372	68.52	gold quality
stomach	UBERON:0000945	67.14	gold quality
islet of Langerhans	UBERON:0000006	65.43	gold quality
fundus of stomach	UBERON:0001160	65.22	gold quality
endocervix	UBERON:0000458	64.99	gold quality
right lung	UBERON:0002167	64.98	gold quality
urinary bladder	UBERON:0001255	63.35	gold quality
pancreas	UBERON:0001264	63.24	gold quality
ganglionic eminence	UBERON:0004023	63.20	gold quality
fallopian tube	UBERON:0003889	63.03	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

63 targeting RNF39, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053

Literature-anchored findings (GeneRIF, showing 3)

• these findings suggest that RNF39 and TRIM39 are involved in the etiology of Behcet’s disease. (PMID:20875797)
• Results identified RNF39 as cis methylation quantitative trait loci in both allergic rhinitis and asthma. (PMID:28149331)
• The findings provide evidence that hypermethylation in an independent MHC locus, RNF39, is also associated with relapsing-remitting multiple sclerosis. (PMID:28729889)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rnf39	ENSMUSG00000036492
rattus_norvegicus	Rnf39	ENSRNOG00000000781
rattus_norvegicus		ENSRNOG00000079068

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890)

Protein

Protein identifiers

RING finger protein 39 — Q9H2S5 (reviewed: Q9H2S5)

Alternative names: Protein HZFw

All UniProt accessions (1): Q9H2S5

UniProt curated annotations — full annotation on UniProt →

Function. Plays an inhibitory role in anti-RNA viral innate immunity by targeting the adapter DDX3X and promoting its ‘Lys-48’-linked polyubiquitination. Alternatively, enhances the cGAS-STING pathway activation by promoting ‘Lys-63’-linked ubiquitination of STING1, facilitating the STING1-TBK1 complex formation and STING1 activation. (Microbial infection) Plays a positive role in human immunodeficiency virus (HIV-1) replication.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in testis.

Pathway. Protein modification; protein ubiquitination.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9H2S5-1	1, HZFW1	yes
Q9H2S5-2	2, HZFW2
Q9H2S5-3	3, HZFW3

RefSeq proteins (2): NP_079512, NP_739575 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR003879	Butyrophylin_SPRY	Domain
IPR006574	PRY	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR027370	Znf-RING_euk	Domain
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050143	TRIM/RBCC	Family

Pfam: PF00622, PF13445, PF13765

UniProt features (11 total): sequence variant 4, splice variant 3, chain 1, domain 1, mutagenesis site 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H2S5-F1	66.27	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
108	complete loss of e3 ligase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 122 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, XU_GH1_AUTOCRINE_TARGETS_UP, NKX25_02, CHX10_01, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, SRF_C, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION

GO Biological Process (7): negative regulation of cytoplasmic pattern recognition receptor signaling pathway (GO:0039532), innate immune response (GO:0045087), protein K63-linked ubiquitination (GO:0070534), positive regulation of cGAS/STING signaling pathway (GO:0141111), cytoplasmic pattern recognition receptor signaling pathway (GO:0002753), positive regulation of type I interferon production (GO:0032481), cGAS/STING signaling pathway (GO:0140896)

GO Molecular Function (5): zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasmic pattern recognition receptor signaling pathway	2
regulation of cytoplasmic pattern recognition receptor signaling pathway	2
positive regulation of cytokine production	2
negative regulation of immune system process	1
negative regulation of intracellular signal transduction	1
immune response	1
defense response to symbiont	1
protein polyubiquitination	1
positive regulation of pattern recognition receptor signaling pathway	1
cGAS/STING signaling pathway	1
positive regulation of intracellular signal transduction	1
pattern recognition receptor signaling pathway	1
intracellular receptor signaling pathway	1
regulation of type I interferon production	1
type I interferon production	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

761 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNF39	HLA-F	P30511	796
RNF39	POLR1H	Q9P1U0	708
RNF39	HLA-A	P01891	682
RNF39	C10orf105	Q8TEF2	578
RNF39	TCF19	Q9Y242	560
RNF39	CFAP92	Q9ULG3	515
RNF39	TRIM31	Q9BZY9	513
RNF39	CDSN	Q15517	494
RNF39	CCHCR1	Q8TD31	491
RNF39	ZFP57	Q9NU63	447
RNF39	ABCF1	Q8NE71	440
RNF39	PPP1R11	O60927	435
RNF39	PSMC5	P47210	433
RNF39	ZNF57	Q68EA5	428
RNF39	PRKACA	P17612	421
RNF39	PRKACG	P22612	421

IntAct

22 interactions, top by confidence:

A	B	Type	Score
RNF39	DNAAF6	psi-mi:“MI:0915”(physical association)	0.560
KRT27	RNF39	psi-mi:“MI:0915”(physical association)	0.560
GOLGA6L9	RNF39	psi-mi:“MI:0915”(physical association)	0.560
RABEP1	RNF39	psi-mi:“MI:0915”(physical association)	0.560
AP1B1	RNF39	psi-mi:“MI:0915”(physical association)	0.560
MORN3	RNF39	psi-mi:“MI:0915”(physical association)	0.560
RINT1	RNF39	psi-mi:“MI:0915”(physical association)	0.560
RNF39	DNAAF6	psi-mi:“MI:0915”(physical association)	0.000
RNF39	KRT27	psi-mi:“MI:0915”(physical association)	0.000
RNF39	GOLGA6L9	psi-mi:“MI:0915”(physical association)	0.000
RNF39	RABEP1	psi-mi:“MI:0915”(physical association)	0.000
RNF39	AP1B1	psi-mi:“MI:0915”(physical association)	0.000
RNF39	MORN3	psi-mi:“MI:0915”(physical association)	0.000
RNF39	RINT1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): RNF39 (Two-hybrid), RNF39 (Two-hybrid), RNF39 (Two-hybrid), RNF39 (Two-hybrid), RNF39 (Two-hybrid), RNF39 (Two-hybrid), RNF39 (Two-hybrid), RNF39 (Affinity Capture-Western), RNF39 (Affinity Capture-Western), TP53 (Affinity Capture-Western)

ESM2 similar proteins: A0A0U1RR11, A0A0U1RRI6, A6NCS6, A6NJG2, B0BN44, D3YXK1, E9PY61, E9Q0B3, F5H4A9, O00220, O00221, P09038, P0DPI3, P22083, P98077, Q08AU9, Q2M2W7, Q2M3V2, Q2TBI2, Q5F267, Q5FW56, Q5IS69, Q5R866, Q5T4W7, Q5TM52, Q5U4P2, Q5VTJ3, Q659K9, Q673H1, Q69ZB3, Q6AYE8, Q6IPT2, Q6PJ61, Q7RTU4, Q7TSX9, Q7YR31, Q80SU3, Q86SH2, Q86Y97, Q8NBR0

Diamond homologs: A0A3B3IT33, A0JN74, A2XK56, A4QPC6, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NLI5, A6NLU0, B1H278, B8B5U8, C9J1S8, D3YY23, D3Z8N2, F8VTS6, I1YAP6, O00478, O00481, O13033, O54952, O60106, O76064, P0CI25, P0CI26, P18892, P19474, P38398, P48754, P82456, P86448, P86449, Q14258, Q14527, Q1XHT8, Q28DS3, Q2HJ46, Q3C1V9, Q3TL54, Q4KLN8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	RNF39	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

740 predictions. Top by Δscore:

Variant	Effect	Δscore
6:30073151:CCTTA:C	donor_loss	1.0000
6:30073152:CTTA:C	donor_loss	1.0000
6:30073153:TTACC:T	donor_loss	1.0000
6:30073154:TA:T	donor_loss	1.0000
6:30073155:A:AG	donor_loss	1.0000
6:30073156:C:CT	donor_loss	1.0000
6:30073156:CCTGT:C	donor_gain	1.0000
6:30073244:CAAAT:C	acceptor_gain	1.0000
6:30073245:AAAT:A	acceptor_gain	1.0000
6:30073246:AAT:A	acceptor_gain	1.0000
6:30073247:AT:A	acceptor_gain	1.0000
6:30073249:C:CC	acceptor_gain	1.0000
6:30073250:T:A	acceptor_loss	1.0000
6:30073254:C:CT	acceptor_gain	1.0000
6:30073489:C:CT	acceptor_gain	1.0000
6:30073490:A:T	acceptor_gain	1.0000
6:30071689:CGG:C	acceptor_gain	0.9900
6:30071692:C:CC	acceptor_gain	0.9900
6:30071699:C:CT	acceptor_gain	0.9900
6:30073155:A:AC	donor_gain	0.9900
6:30073156:C:CC	donor_gain	0.9900
6:30073246:AATCT:A	acceptor_gain	0.9900
6:30073247:ATCT:A	acceptor_gain	0.9900
6:30073255:A:T	acceptor_gain	0.9900
6:30073257:A:AC	acceptor_gain	0.9900
6:30073257:A:C	acceptor_gain	0.9900
6:30073451:CTCA:C	donor_loss	0.9900
6:30073452:TCA:T	donor_loss	0.9900
6:30073453:CA:C	donor_loss	0.9900
6:30073454:A:AC	donor_gain	0.9900

AlphaMissense

2654 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:30071204:G:C	F390L	0.993
6:30071204:G:T	F390L	0.993
6:30071206:A:G	F390L	0.993
6:30071516:C:A	W286C	0.993
6:30071516:C:G	W286C	0.993
6:30071240:G:C	F378L	0.991
6:30071240:G:T	F378L	0.991
6:30071242:A:G	F378L	0.991
6:30071573:G:C	F267L	0.991
6:30071573:G:T	F267L	0.991
6:30071575:A:G	F267L	0.991
6:30075528:A:G	C88R	0.991
6:30071518:A:G	W286R	0.990
6:30071518:A:T	W286R	0.990
6:30075467:C:T	C108Y	0.989
6:30071241:A:G	F378S	0.988
6:30075469:G:C	F107L	0.988
6:30075469:G:T	F107L	0.988
6:30075471:A:G	F107L	0.988
6:30075352:A:C	N146K	0.986
6:30075352:A:T	N146K	0.986
6:30075468:A:G	C108R	0.986
6:30071280:A:G	I365T	0.985
6:30075497:G:T	P98Q	0.984
6:30075326:A:G	I155T	0.983
6:30075466:G:C	C108W	0.983
6:30075527:C:T	C88Y	0.983
6:30075472:G:C	S106R	0.982
6:30075472:G:T	S106R	0.982
6:30075474:T:G	S106R	0.982

dbSNP variants (sampled 300 via entrez): RS1000209541 (6:30074167 C>G), RS1000302971 (6:30074377 G>A), RS1000417246 (6:30071585 G>A), RS1000542037 (6:30072388 A>G), RS1000750123 (6:30072941 C>A), RS1001215432 (6:30075423 C>G,T), RS1001589928 (6:30071047 T>G), RS1001768790 (6:30077159 T>C), RS1003057991 (6:30072281 G>A), RS1003366347 (6:30071494 C>A,T), RS1003387282 (6:30070680 A>G), RS1004735656 (6:30076395 T>G), RS1006168389 (6:30071919 G>A), RS1006211776 (6:30076803 C>A,T), RS1006829034 (6:30070188 C>T)

Disease associations

OMIM: gene MIM:607524 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST000308_3	AIDS progression	5.000000e-07
GCST000549_24	HIV-1 control	2.000000e-08
GCST002324_6	Anger	8.000000e-07
GCST004521_12	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_121	Autism spectrum disorder or schizophrenia	3.000000e-13
GCST004521_171	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_177	Autism spectrum disorder or schizophrenia	3.000000e-12
GCST004521_2	Autism spectrum disorder or schizophrenia	2.000000e-16
GCST004521_210	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_216	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_218	Autism spectrum disorder or schizophrenia	5.000000e-11
GCST004521_247	Autism spectrum disorder or schizophrenia	4.000000e-09
GCST004521_263	Autism spectrum disorder or schizophrenia	7.000000e-17
GCST004521_268	Autism spectrum disorder or schizophrenia	7.000000e-12
GCST004521_269	Autism spectrum disorder or schizophrenia	7.000000e-11
GCST004521_295	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_3	Autism spectrum disorder or schizophrenia	2.000000e-15
GCST004521_44	Autism spectrum disorder or schizophrenia	2.000000e-17
GCST004521_51	Autism spectrum disorder or schizophrenia	9.000000e-14
GCST004521_56	Autism spectrum disorder or schizophrenia	1.000000e-22
GCST004521_58	Autism spectrum disorder or schizophrenia	1.000000e-17
GCST004521_59	Autism spectrum disorder or schizophrenia	1.000000e-11
GCST004521_70	Autism spectrum disorder or schizophrenia	8.000000e-20
GCST004521_79	Autism spectrum disorder or schizophrenia	1.000000e-16
GCST004521_80	Autism spectrum disorder or schizophrenia	1.000000e-15
GCST004521_92	Autism spectrum disorder or schizophrenia	1.000000e-11
GCST004623_17	Neutrophil percentage of granulocytes	2.000000e-30
GCST006269_1232	General cognitive ability	5.000000e-08
GCST008436_1	Nonobstructive coronary artery disease	7.000000e-07
GCST009391_776	Metabolite levels	7.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0000180	HIV-1 infection
EFO:0003015	aggressive behavior
EFO:0007994	neutrophil percentage of granulocytes
EFO:0004337	intelligence
EFO:1001483	non-obstructive coronary artery disease
EFO:0010393	sphingomyelin 18:0 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Phthalic Acids	affects methylation, decreases methylation, increases abundance	2
Silicon Dioxide	increases expression	2
aristolochic acid I	increases expression	1
aminomethylphosphonic acid (AMPA)	affects methylation, increases abundance	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
1-hydroxypyrene	affects cotreatment, decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Decitabine	affects expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Glyphosate	increases abundance, affects methylation	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cadmium	decreases expression	1
Calcitriol	increases expression	1
Cisplatin	affects expression	1
Estradiol	affects cotreatment, decreases expression	1
Nickel	decreases expression	1
Smoke	increases expression	1
Sodium Dodecyl Sulfate	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Asbestos, Crocidolite	increases expression	1
Metals, Heavy	affects cotreatment, decreases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.